Tag: OCRA Research

OCRA-Funded Study Reveals Promising Therapeutic Option for Boosting Ovarian Cancer Immune Response

Targeting a specific oncogene associated with the most common type of ovarian cancer may help increase a patient’s immune response to tumors, according to recent findings from researchers at The Wistar Institute and their colleagues at University…

Read on

New Bioinformatics Tool Shows Promise for Matching Cancer Patients with Optimal Treatment Combinations

Recent OCRA-funded research has resulted in the creation of a new bioinformatics tool that holds potential for predicting the best treatment combinations for cancer patients…

Read on

OCRA Awards Two Ovarian Cancer Research Prizes

OCRA is pleased to announce the recipients of two research prizes, selected by members of our Scientific Advisory Committee for their notable contributions to the field of ovarian cancer research and commitment to future discoveries. Dr…

Read on

OCRA-Funded Research Points to Potential for Predicting Ovarian Cancer

New study findings not only reveal where the most common ovarian cancer subtype originates in certain patients, but also point to the future possibility of being able to predict who will get the disease…

Read on

OCRA Awards Nearly $6.5 Million in Ovarian Cancer Research Grants

More breakthroughs are on the horizon, as OCRA has awarded grants to 22 dedicated scientists at 15 prestigious medical institutions to enable future ovarian cancer discoveries…

Read on

Anne van Harten, PhD | Meet a Scientist

Dr. Anne van Harten, of the Sidney Kimmel Cancer Center at Thomas Jefferson University in Philadelphia, is a 2021 recipient of OCRA’s Ann and Sol Schreiber Mentored Investigator Award…

Read on

OCRA-Funded Research Reveals How Distinct Mutational Processes May Affect HGSOC Tumor Growth

OCRA grantees Ignacio Vázquez-García, PhD and Sohrab Shah, PhD, of Memorial Sloan Kettering Cancer Center, along with colleagues, have found that distinct mutational processes determine the different mechanisms by which certain…

Read on

The Overview: December 2021

This time of year always has us reflecting on what we’ve accomplished, what we hope to achieve in the future, and how we — with the support of the entire ovarian cancer community — can lean in even harder to our commitment…

Read on

OCRA-Funded Research Identifies New “Master” Drug Targets for Ovarian Cancer

An interdisciplinary group of researchers from around the country analyzed tumor samples from nearly 10,000 patients with 34 types of cancer to reveal unique genetic switches associated with each tumor type…

Read on

OCRA-Funded Study Identifies Antibiotic Found to Kill Tumor Cells Containing BRCA Mutations

A long-running study from Dana-Farber Cancer Institute, published in Nature Cancer and co-funded by OCRA, has discovered that the antibiotic novobiocin is capable of targeting and killing tumor cells in laboratory cell lines and tumor models with…

Read on

OCRA-Funded Research Provides a New Understanding of Ovarian Cancer Biology

OCRA-funded researcher Anil K. Sood, M.D., lead and senior author, and Sanghoon Lee, Ph.D…

Read on

OCRA-Funded Research Discoveries in 2020

It’s hard to believe 2020 is almost over, and what a year it’s been…

Read on
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]